JP2021512951A5 - - Google Patents

Info

Publication number
JP2021512951A5
JP2021512951A5 JP2020564033A JP2020564033A JP2021512951A5 JP 2021512951 A5 JP2021512951 A5 JP 2021512951A5 JP 2020564033 A JP2020564033 A JP 2020564033A JP 2020564033 A JP2020564033 A JP 2020564033A JP 2021512951 A5 JP2021512951 A5 JP 2021512951A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
alkoxy
amide
pharmaceutically acceptable
Prior art date
Application number
JP2020564033A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512951A (ja
JPWO2019152911A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/016477 external-priority patent/WO2019152911A1/en
Publication of JP2021512951A publication Critical patent/JP2021512951A/ja
Publication of JP2021512951A5 publication Critical patent/JP2021512951A5/ja
Publication of JPWO2019152911A5 publication Critical patent/JPWO2019152911A5/ja
Priority to JP2024019158A priority Critical patent/JP2024073414A/ja
Pending legal-status Critical Current

Links

JP2020564033A 2018-02-02 2019-02-04 ゲムシタビン誘導体の新規小分子薬物コンジュゲート Pending JP2021512951A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024019158A JP2024073414A (ja) 2018-02-02 2024-02-13 ゲムシタビン誘導体の新規小分子薬物コンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862625779P 2018-02-02 2018-02-02
US62/625,779 2018-02-02
PCT/US2019/016477 WO2019152911A1 (en) 2018-02-02 2019-02-04 Novel small molecule drug conjugates of gemcitabine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024019158A Division JP2024073414A (ja) 2018-02-02 2024-02-13 ゲムシタビン誘導体の新規小分子薬物コンジュゲート

Publications (3)

Publication Number Publication Date
JP2021512951A JP2021512951A (ja) 2021-05-20
JP2021512951A5 true JP2021512951A5 (https=) 2022-02-14
JPWO2019152911A5 JPWO2019152911A5 (https=) 2022-02-14

Family

ID=65494546

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564033A Pending JP2021512951A (ja) 2018-02-02 2019-02-04 ゲムシタビン誘導体の新規小分子薬物コンジュゲート
JP2024019158A Pending JP2024073414A (ja) 2018-02-02 2024-02-13 ゲムシタビン誘導体の新規小分子薬物コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024019158A Pending JP2024073414A (ja) 2018-02-02 2024-02-13 ゲムシタビン誘導体の新規小分子薬物コンジュゲート

Country Status (13)

Country Link
US (1) US20210380626A1 (https=)
EP (1) EP3746133A1 (https=)
JP (2) JP2021512951A (https=)
KR (1) KR20200118828A (https=)
CN (1) CN112135635A (https=)
AU (1) AU2019216514A1 (https=)
BR (1) BR112020015747A2 (https=)
CA (1) CA3090272A1 (https=)
EA (1) EA202091857A1 (https=)
IL (1) IL276442A (https=)
PH (1) PH12020551178A1 (https=)
SG (1) SG11202007381YA (https=)
WO (1) WO2019152911A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210367A1 (es) * 2018-02-02 2021-02-26 Maverix Oncology Inc Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina
CN114349816B (zh) * 2021-11-30 2024-08-30 潍坊博创国际生物医药研究院 一种基于氨肽酶n/cd13的小分子偶联分子及其制备方法和应用
WO2026009986A1 (ja) * 2024-07-05 2026-01-08 学校法人東京理科大学 化合物の製造方法及び化合物
WO2026009987A1 (ja) * 2024-07-05 2026-01-08 学校法人東京理科大学 化合物の製造方法、化合物、及びヌクレオチドプロドラッグ前駆体
CN119708099B (zh) * 2024-12-23 2025-10-24 中国药科大学 吉西他滨前药及其医药用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2531599A (en) 1998-02-12 1999-08-30 De Montfort University Hydroxylation activated drug release
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
JP6212831B2 (ja) * 2013-12-04 2017-10-18 杭州源昶医薬科技有限公司 ゲムシタビン誘導体、該誘導体を含む組成物及び該誘導体の製薬用途
WO2015134334A1 (en) * 2014-03-03 2015-09-11 Suo Zucai Gemcitabine analogs
CN105001291B (zh) * 2014-04-15 2018-12-04 上海知萌生物医药科技有限公司 吉西他滨化学传递前药及其制备方法和应用
US20180044368A1 (en) * 2015-02-25 2018-02-15 Ligand Pharmaceuticals, Inc. Gemcitabine derivatives

Similar Documents

Publication Publication Date Title
JP2021512951A5 (https=)
JP7605892B2 (ja) Ｔｅａｄ転写因子の新規小分子阻害剤
TWI843712B (zh) Ｋ他命的前藥及其組成物及用途
ES2393551T3 (es) Compuestos bicíclicos novedosos y composiciones
DK2461683T3 (en) Bicyclic aryl-sphingosine-1-phosphate analogues
BRPI0709608A2 (pt) derivado de quinolona ou sal farmaceuticamente aceitável deste
JP2003528146A (ja) 脳血管疾患の治療
BR112016013572B1 (pt) Composto (6s,9as)-n-benzil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3- (piperazina-1-il)azetidina-1-il]piridina-2-il}metil)-2-(prop-2-en-1-il)-octaidro-1hpirazino[2,1-c][1,2,4]triazina-1-carboxamida
BRPI0707281A2 (pt) método para prevenção ou tratamento de dor neuropática em um mamìfero
JP2018016652A (ja) リポイル化合物および虚血性傷害を治療するためのその使用
AU2019278992A1 (en) Cannabinoids and uses thereof
JP2026506777A (ja) 甲状腺ホルモン類似体のプロドラッグ、その製造方法および使用方法
JPH0341027A (ja) 〔３‐（ｃ↓１↓６〜ｃ↓１↓８）アルカンスルフィニル―及びスルホニル‐２‐メトキシメチル―プロピル〕‐（２‐トリメチルアンモニオ―エチル）ホスフェート、その製造方法及びその化合物を含有する医薬
JPWO2019152911A5 (https=)
JP2021512953A5 (https=)
MX2023008250A (es) Compuestos de derivados sustituidos en 4,6 de ip4.
US10487045B2 (en) Adamantane derivative and use thereof
CN115427410A (zh) 酰胺或者磺酰胺类衍生物及其应用
JP2018080118A (ja) 損傷治療剤
WO2015154716A1 (zh) 菲罗啉膦酸类衍生物及其制备方法和应用
FR2859208B1 (fr) Nouveaux derives de 9-amino-podophyllotoxine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2024234619A1 (zh) 一种化合物的晶型、药物组合物及用途
EP4419509A1 (en) Compounds and compositions for treating conditions associated with lpa receptor activity
CA3176429A1 (en) Modulators of hemoglobin
WO2022118966A1 (ja) 細胞内への核酸分子取り込み促進剤、医薬組成物、及び新規化合物